Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study
Reinhard Dummer, Henry M Prince, Sean Whittaker, et al.
The Journal of Investigative Dermatology
|
March 2, 2016
Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients
Stephanie E Boonk, Willem H Zoutman, Anne Marie-Cardine, et al.
Journal of Cutaneous Pathology
|
November 19, 2005
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects
Günter Burg, Werner Kempf, Antonio Cozzio, et al.
Blood
|
October 16, 2007
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases
Rein Willemze, Patty M Jansen, Lorenzo Cerroni, et al.
The British Journal of Dermatology
|
January 6, 2022
Clinical, histopathological and prognostic features of primary cutaneous acral CD8<sup>+</sup> T-cell lymphoma and other dermal CD8<sup>+</sup> cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop
Werner Kempf, Tony Petrella, Rein Willemze, et al.
Blood
|
November 10, 2021
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Elise A Olsen, Sean Whittaker, Rein Willemze, et al.
Lancet (London, England)
|
June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H Miles Prince, Youn H Kim, Steven M Horwitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
Youn H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A Olsen, Sean Whittaker, Youn H Kim, et al.
The Lancet. Oncology
|
August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study
Reinhard Dummer, Henry M Prince, Sean Whittaker, et al.
The Journal of Investigative Dermatology
|
March 2, 2016
Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients
Stephanie E Boonk, Willem H Zoutman, Anne Marie-Cardine, et al.
Journal of Cutaneous Pathology
|
November 19, 2005
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects
Günter Burg, Werner Kempf, Antonio Cozzio, et al.
Blood
|
October 16, 2007
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases
Rein Willemze, Patty M Jansen, Lorenzo Cerroni, et al.
The British Journal of Dermatology
|
January 6, 2022
Clinical, histopathological and prognostic features of primary cutaneous acral CD8<sup>+</sup> T-cell lymphoma and other dermal CD8<sup>+</sup> cutaneous lymphoproliferations: results of an EORTC Cutaneous Lymphoma Group workshop
Werner Kempf, Tony Petrella, Rein Willemze, et al.
Blood
|
November 10, 2021
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Elise A Olsen, Sean Whittaker, Rein Willemze, et al.
Lancet (London, England)
|
June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H Miles Prince, Youn H Kim, Steven M Horwitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
Youn H Kim, H Miles Prince, Sean Whittaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2011
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A Olsen, Sean Whittaker, Youn H Kim, et al.
The Lancet. Oncology
|
August 14, 2018
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H Kim, Martine Bagot, Lauren Pinter-Brown, et al.
Page
of 9